Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41467-021-21444-5 http://scihub22266oqcxt.onion/10.1038/s41467-021-21444-5 33608522!7896046!33608522     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Commun 2021 ; 12 (1): 1162 Nephropedia Template TP {{tp|p=33608522|t=2021. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19 |pdf=|usr=}}{{33608522}} gab.com Text Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19 JO: Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=33608522 #FOAvip The durability of infection-induced SARS-CoV-2 immunity has major implications for reinfection and vaccine development. Here, we show a comprehensive profile of antibody, B cell and T cell dynamics over time in a cohort of patients who have recovered from mild-moderate COVID-19. Binding and neutralising antibody responses, together with individual serum clonotypes, decay over the first 4 months post-infection. A similar decline in Spike-specific CD4(+) and circulating T follicular helper frequencies occurs. By contrast, S-specific IgG(+) memory B cells consistently accumulate over time, eventually comprising a substantial fraction of circulating the memory B cell pool. Modelling of the concomitant immune kinetics predicts maintenance of serological neutralising activity above a titre of 1:40 in 50% of convalescent participants to 74 days, although there is probably additive protection from B cell and T cell immunity. This study indicates that SARS-CoV-2 immunity after infection might be transiently protective at a population level. Therefore, SARS-CoV-2 vaccines might require greater immunogenicity and durability than natural infection to drive long-term protection. Twit Text FOAVip Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19 ????Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=33608522 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33608522 #FOAvip English Wikipedia <ref>{{Cite pmid|33608522}}</ref> Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19 #MMPMID33608522 Wheatley AK; Juno JA; Wang JJ; Selva KJ; Reynaldi A; Tan HX; Lee WS; Wragg KM; Kelly HG; Esterbauer R; Davis SK; Kent HE; Mordant FL; Schlub TE; Gordon DL; Khoury DS; Subbarao K; Cromer D; Gordon TP; Chung AW; Davenport MP; Kent SJ Nat Commun 2021[Feb]; 12 (1): 1162 PMID33608522show ga The durability of infection-induced SARS-CoV-2 immunity has major implications for reinfection and vaccine development. Here, we show a comprehensive profile of antibody, B cell and T cell dynamics over time in a cohort of patients who have recovered from mild-moderate COVID-19. Binding and neutralising antibody responses, together with individual serum clonotypes, decay over the first 4 months post-infection. A similar decline in Spike-specific CD4(+) and circulating T follicular helper frequencies occurs. By contrast, S-specific IgG(+) memory B cells consistently accumulate over time, eventually comprising a substantial fraction of circulating the memory B cell pool. Modelling of the concomitant immune kinetics predicts maintenance of serological neutralising activity above a titre of 1:40 in 50% of convalescent participants to 74 days, although there is probably additive protection from B cell and T cell immunity. This study indicates that SARS-CoV-2 immunity after infection might be transiently protective at a population level. Therefore, SARS-CoV-2 vaccines might require greater immunogenicity and durability than natural infection to drive long-term protection. |*Antibody Formation[MESH] |*Immunity, Cellular[MESH] |*Immunologic Memory[MESH] |Antibodies, Neutralizing/blood/immunology[MESH] |Antibodies, Viral/blood/*immunology[MESH] |B-Lymphocytes/immunology[MESH] |CD4-Positive T-Lymphocytes/immunology[MESH] |COVID-19/*immunology[MESH] |Humans[MESH] |Immunoglobulin G/immunology[MESH] |Longitudinal Studies[MESH] |Models, Theoretical[MESH] |Neutralization Tests[MESH]Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19 (epmc).pdf DeepDyve Pubget Overpricing